1. Home
  2. MTZ vs EXAS Comparison

MTZ vs EXAS Comparison

Compare MTZ & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MasTec Inc.

MTZ

MasTec Inc.

HOLD

Current Price

$275.54

Market Cap

17.4B

Sector

Industrials

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$103.27

Market Cap

19.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTZ
EXAS
Founded
1929
1995
Country
US
US
Employees
N/A
N/A
Industry
Water Sewer Pipeline Comm & Power Line Construction
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.4B
19.6B
IPO Year
2005
2000

Fundamental Metrics

Financial Performance
Metric
MTZ
EXAS
Price
$275.54
$103.27
Analyst Decision
Strong Buy
Buy
Analyst Count
20
19
Target Price
$238.42
$84.27
AVG Volume (30 Days)
726.0K
2.2M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
421.88
80.32
EPS
3.26
N/A
Revenue
$12,303,464,000.00
$4,144,000.00
Revenue This Year
$15.50
$15.18
Revenue Next Year
$10.18
$12.46
P/E Ratio
$81.15
N/A
Revenue Growth
2.56
N/A
52 Week Low
$99.70
$38.88
52 Week High
$276.79
$103.87

Technical Indicators

Market Signals
Indicator
MTZ
EXAS
Relative Strength Index (RSI) 69.75 67.66
Support Level $259.93 $103.14
Resistance Level $276.79 $103.42
Average True Range (ATR) 11.95 0.34
MACD 1.23 -0.13
Stochastic Oscillator 94.10 67.53

Price Performance

Historical Comparison
MTZ
EXAS

About MTZ MasTec Inc.

MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: